Home Members Tools Credit Cards
   

RIGL Stock Quote and Technical Analysis

Portfolios Markets Resources
  Symbol List
Rigel Pharmaceuticals, Inc. (RIGL)
▼ 2.99 (-0.15) -4.78%
Open: 3.11
High: 3.22
Low: 2.95
Afterhours: N/A - N/A
Volume: 1037646
2/27/2015 4:00pm
 
Interactive Chart
EPS: -0.976 (Current Year Estimated: -1.04)
Dividend: N/A
P/E: N/A

Technicals:
52 Week Range: 1.56 - 5.00
50 Day Moving Average: 2.3877
200 Day Moving Average: 2.2185
Pivot Point (Next Trading Session): 3.05

Login or signup free to Add "RIGL" to your portfolio

Resources:

News:


Rigel Pharma CEO pulls back the curtain on drug deal with Bristol-Myers
Thu, 26 Feb 2015 14:45:12 GMT


Bristol-Myers to Buy Flexus, Team Up with Rigel - Analyst Blog
Tue, 24 Feb 2015 23:54:11 GMT


BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Digital Ally, Home Loan Servicing
Mon, 23 Feb 2015 15:13:25 GMT


BUZZ-U.S. STOCKS ON THE MOVE-Rigel, oil stocks, Boeing
Mon, 23 Feb 2015 14:30:57 GMT


Is Rigel Getting Enough From Bristol-Meyers?
Mon, 23 Feb 2015 14:15:37 GMT


Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
Mon, 23 Feb 2015 13:23:27 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif. and NEW YORK, February 23, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered ...

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
Mon, 23 Feb 2015 13:21:04 GMT
[at noodls] - Dateline: SOUTH SAN FRANCISCO, Calif. & NEW YORK "This collaboration places our TGF beta receptor kinase inhibitor program into the hands of Bristol-Myers Squibb, a premier immuno-oncology company. ...

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
Mon, 23 Feb 2015 13:03:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif. and NEW YORK, February 23, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered ...

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
Mon, 23 Feb 2015 13:00:00 GMT
[Business Wire] - Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors.

Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee
Tue, 17 Feb 2015 13:00:00 GMT
[GlobeNewswire] - LOS ANGELES -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its board ...

RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Fri, 30 Jan 2015 21:06:20 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Fri, 09 Jan 2015 21:16:33 GMT


Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Thu, 08 Jan 2015 12:57:10 GMT
[at noodls] - SOUTH SAN FRANCISCO, Jan. 8, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present updated ...

Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Thu, 08 Jan 2015 12:30:00 GMT
[PR Newswire] - AstraZeneca's continued efforts to develop R256, Rigel's inhaled JAK inhibitor, as a potential treatment for asthma, triggered a milestone payment of $5.75 million that Rigel earned in December 2014. AstraZeneca and Rigel entered an exclusive worldwide license agreement for the global development and commercialization of R256 in June 2012. Partners BerGenBio and Daiichi Sankyo are developing Rigel's AXL kinase inhibitor and an ubiquitin ligase inhibitor, respectively, for their potential safety and efficacy in treating various cancers. Both of these molecules are currently in Phase 1 clinical development.

Art Levinson's aging research company Calico snags South S.F. space
Wed, 24 Dec 2014 18:20:09 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Mon, 24 Nov 2014 21:16:19 GMT


Rigel Announces Executive Management Changes
Mon, 24 Nov 2014 12:44:03 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as chairman ...

Rigel Announces Executive Management Changes
Mon, 24 Nov 2014 12:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as the company's president and chief operating officer, will assume the position of chief executive officer and join the board of directors. Gary Lyons, a member of Rigel's Board of Directors since 2005, will become chairman. Mr. Gower is expected to remain an employee until the end of the year and, thereafter will be a consultant to the company providing advice on strategy, business development and other matters.

RIGEL PHARMACEUTICALS INC Financials
Fri, 14 Nov 2014 18:04:38 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Tue, 04 Nov 2014 21:20:12 GMT


All Company News is Powered by Yahoo! Finance

 

 

 

Credit Cards | Finance Social Network | Credit Card Reviews | Markets
About Us | FG on the Web | Sitemap | Privacy | Terms | Contact


Copyright © 2015 Finance Globe. All rights reserved.